Evidence map›Paper›PMID 16379041›Full record

ArticleInvestigational new drugs2006

The combination of sulfinosine and 8-Cl-cAMP induces synergistic cell growth inhibition of the human neuroblastoma cell line in vitro.

Dragana Janković, Milica Pesić, Jasna Marković, Selma Kanazir, Ivanka Marković, Ljubisav Rakić, Sabera Ruzdijić

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Dragana JankovićDepartment of Neurobiology and Immunology, Institute for Biological Research, Belgrade, 11060, Serbia & Montenegro.
Milica Pesić
Jasna Marković
Selma Kanazir
Ivanka Marković
Ljubisav Rakić
Sabera Ruzdijić
Institute of Neurobiology · BGSerbian Academy of Sciences and Arts · RSUniversity of Belgrade · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To identify purine analogs that could be effective in treating neuroblastomas, we tested the anticancer properties of sulfinosine, 8-Cl-cAMP and 8-Cl-adenosine in the SK-N-SH cell line. First we examined the effects of these three agents on cell growth inhibition and cell viability by the BrdU and Sulforhodamine B assay. Treatment of SK-N-SH cells with increasing concentrations of these compounds led to a significant inhibition of cell proliferation and decrease of cell viability in a time- and dose-dependent manner at micromolar concentration (<10 microm). Treatment with a combination of sulfinosine and 8-Cl-cAMP resulted in synergistic effects on growth inhibition, cell cycle arrest and induction of apoptosis. Flow-cytometric analysis showed that 8-Cl-cAMP arrested the cells in the G0/G1 phase and sulfinosine blocked cell cycle progression at the G2/M stage, in contrast to the combined effects of both agents that did not arrest growth at any particular phase of the cell cycle. Further analysis of apoptosis induction demonstrated an increase from 17 to 24% of both early and late apoptotic cells and a very low percentage of necrotic cells. These results indicate that apoptosis was the predominant type of cell death after treatment of SK-N-SH cells with both substances, as well as with their combinations.

Indexed as

2-Chloroadenosine8-Bromo Cyclic Adenosine MonophosphateAntineoplastic AgentsApoptosisCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug SynergismHumansNeuroblastomaPurine NucleosidesTime Factors2-Chloroadenosine8-Bromo Cyclic Adenosine Monophosphate8-chloroadenosine8-chloro-cyclic adenosine monophosphateAntineoplastic AgentsPurine Nucleosidessulfinosine

Identifiers

PMID16379041
OpenAlexW2021451750

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.